When Will Glaxo Get Its Stories Straight About The Scandal?

esilverman For the past couple of weeks, GlaxoSmithKline officials have worked hard to appear diligent and contrite as they go about controlling the damage from the sensational ...

Sarepta to Submit NDA for Eteplirsen

barbara.lempert Sarepta Therapeutics Announces Plans to Submit New Drug Application to FDA for Eteplirsen for the Treatment of Duchenne Muscular Dystrophy in First Half of ...

InterMune Reports Second Quarter 2013 Financial Results And Business Highlights

barbara.lempert — Reports 7th Consecutive Quarter of Esbriet Revenue Growth–   BRISBANE, Calif., July 24, 2013 /PRNewswire/ — InterMune, Inc. (NASDAQ: ITMN) today ...

Transition Therapeutics makes licensing pact for Lilly arthritis drug

Emily Mullin Toronto-based Transition Therapeutics today announced that it has acquired exclusive licensing of worldwide rights for Eli Lilly's experimental drug TT-601 for arthritis ...

Galectin Therapeutics Doses First Patient in GR-MD-02 Trial

mia.burns Galectin Therapeutics Announces First Patient Dosed in Phase 1 Trial of GR-MD-02, a Potential First-in-Class Treatment for Fatty Liver Disease with Advanced Fibrosis   Norcross, ...

GlaxoSmithKline CEO says HQ, British execs ‘knew nothing’ of China fraud

Tracy Staton GlaxoSmithKline CEO Andrew Witty faced a flurry of questions about China when he stood up to talk about second-quarter earnings–and he bowed out of the conference ...

Roche highlights more upbeat PhIII data for ‘breakthrough’ leukemia contender

Ryan McBride FierceBiotech News

Vivus officially names ex-AstraZeneca exec Zook as new CEO

Carly Helfand The dust is settling over at Vivus after an intense proxy fight that top shareholder First Manhattan Co. waged for months leading up to last week's shareholder meeting. ...

Cytokinetics patches up ALS drug trial after costly study snafu

Ryan McBride Forced to remedy an error in a study for a potential ALS drug, Cytokinetics has revealed plans to amend the protocol of the midstage trial with expanded enrollment. FierceBiotech ...

Biogen: Tecfidera link to MS patient’s death ‘unlikely’

Tracy Staton A woman who had used Biogen Idec's new multiple sclerosis pill Tecfidera has died, and the company is investigating the case. She was suffering from a form of pneumonia ...

ChinaGate: Glaxo Issues A Mea Culpa And AstraZeneca Is Questioned

esilverman More bad news for GlaxoSmithKline. Over the weekend, the embattled drugmaker found itself scrambling on several fronts to contain the damage from a bribery scandal ...

EMA OKs Update to Baxter’s Advate SmPC

barbara.lempert European Medicines Agency Approves SmPC Change to Baxter’s ADVATE to Include Information on PK-Guided Dosing Study Personalized, PK-Guided Dosing Shown to ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS